Notice of Intent to Publish a Funding Opportunity Announcement for RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
ID: 354360Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $650K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the RNA Modifications Driving Oncogenesis (RNAMoDO) Initiative, aimed at advancing mechanistic research on RNA modifications that contribute to cancer development. This initiative seeks collaborative research projects that explore the role of mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation and progression, emphasizing the need for interdisciplinary expertise to address the complex interactions of these modifications. The estimated total program funding is $4.9 million, with an award ceiling of $650,000 for up to five projects, and the NOFO is expected to be published in early Fall 2024, with applications due in November 2024. Interested applicants are encouraged to prepare collaborations and can find additional information through the NCI Board of Scientific Advisors presentation linked in the opportunity overview.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)" aimed at advancing research on RNA modifications that contribute to cancer development. This initiative seeks to support collaborative projects that explore the mechanistic roles of mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation and progression, emphasizing the need for a multi-principal investigator approach to address the complex interactions of these modifications. The NIH plans to fund up to five U01 grants with a total budget of $4.9 million, and applications are due by November 4, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-029.html.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at catalyzing innovative research into the molecular mechanisms of RNA modifications related to brain aging and Alzheimer's disease (AD) and related dementias. This initiative seeks exploratory and developmental grant applications (R21) that focus on identifying critical RNA modification sites, understanding their functional impacts, and exploring gene regulation mechanisms relevant to aging and AD, with an emphasis on open-science practices and data sharing through the Alzheimer's Disease Knowledge Portal. Up to $1.4 million is available for five anticipated awards, with individual project budgets capped at $275,000 over a two-year period. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)." This grant aims to support innovative research that elucidates the molecular mechanisms and functional implications of RNA modifications in relation to brain aging and Alzheimer's disease (AD) and related dementias (ADRD), including Lewy body dementia and frontotemporal dementia. The initiative is crucial for advancing understanding in this field, with the ultimate goal of identifying biomarkers and therapeutic targets that could lead to improved health outcomes for affected populations. Eligible applicants can request up to $500,000 in direct costs per year for projects lasting a maximum of five years, with a total funding allocation of $4 million for fiscal year 2025. Applications are due by November 1, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Notice of Intent to Publish a Notice of Funding Opportunity for Social Determinants of Health (SDoH) and Quality of Care Contributors to Cancer Disparities in People with HIV (U01; Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at understanding the impact of social determinants of health (SDoH) on cancer disparities among people with HIV (PWH). This initiative seeks applications for research that explores health disparities throughout the cancer care continuum, including aspects such as screening, diagnosis, treatment, quality of life, and survivorship, with the goal of enhancing the NIH's research portfolio in this critical area. The funding opportunity, which will utilize the U01 cooperative agreement mechanism, anticipates awarding approximately four grants with a ceiling of $500,000 each, contributing to an estimated total program funding of $3 million. Interested applicants should prepare for the expected publication of the NOFO in fall 2024, with application deadlines projected for winter 2025, 2026, and 2027, and an anticipated award date of July 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at researching the intersection of cancer stigma and HIV stigma in individuals diagnosed with both conditions. This initiative seeks to advance understanding of how these stigmas affect cancer outcomes among HIV-positive individuals, promote stigma reduction interventions, and encourage research in areas with high HIV-cancer burdens. The NIH plans to award up to six R01 grants, each with a ceiling of $500,000, as part of a total estimated funding pool of $5 million, with the NOFO expected to be published in late Summer 2024 and applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing related presentations and materials available online.
    Notice of Intent to Publish a Funding Opportunity Announcement for The confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at exploring the intersection of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This initiative seeks to support pilot and exploratory research that enhances understanding of how these dual stigmas affect cancer outcomes and promotes research in both domestic and international contexts, particularly in regions with a high burden of HIV and cancer. The NIH anticipates funding up to three R21 grants, with a total estimated funding of $1,000,000, and the NOFO is expected to be published in late Summer 2024, with applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing the initiative's presentation and will find further details on the application process following the NOFO publication.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required). This initiative aims to provide statistical expertise for the design, conduct, and data management of multi-center clinical trials, particularly focusing on late-phase treatment trials across various cancer types and patient demographics. The funding, estimated at $47 million, will support approximately five awards, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, interested applicants should prepare their proposals in advance of the anticipated timeline.